5 Stocks to Steer Through Rough Waters

Recs

8

Keeping your portfolio above water in these markets is no easy task. When companies can be whipsawed by the whimsical musings of the Treasury Department or the Fed, an investor who has successfully navigated those rough waters is a rare bird. Doing it over time makes it all the more special.

The All-Stars in the Motley Fool CAPS investor-intelligence database have found themselves particularly adroit at steering their picks through these turbulent markets, and have done so consistently. CAPS has been successfully marking the performance of the best stocks for more than two years now, so we'll look at some of the recent picks of this community's longtime investing mavens.

If these All-Stars have been able to maintain their top status through bull and bear markets, then it might be worth keeping an eye on how they think stocks will perform in the months and years ahead.

CAPS Member

Member Rating

Member Since

Recent Stock Pick

CAPS Rating (out of 5)

Call

TDRH

99.99

10/5/06

Pfizer (NYSE: PFE)

****

Outperform

euphoria96

99.99

11/4/06

Garmin (Nasdaq: GRMN)

****

Outperform

Gtrinvestor

99.98

11/29/06

Western Refining (NYSE: WNR)

***

Outperform

TheGreatSatan

99.98

9/18/06

Dillard's (NYSE: DDS)

*

Underperform

StatsGeek

99.98

12/19/06

Silver Wheaton (NYSE: SLW)

*****

Outperform

Rowing against the current
Pfizer suffered a setback in its attempt to get erectile dysfunction therapy Viagra approved as an over-the-counter medicine in Europe. While the company may reapply at a later date, the short-term prognosis remains pretty grim. That's going to pull sales down for the little blue pill, which already faces tough competition from Eli Lilly's (NYSE: LLY) Cialis, as well as Levitra, which is a joint marketing venture between GlaxoSmithKline (NYSE: GSK), Schering-Plough, and Bayer.

CAPS member rockambo thinks Pfizer has been disappointing lately in a business model based on blockbuster drugs:

so lots of good things are happen to this company, but they haven't recovered from the blockbuster business model and there's about one potential drug in the pipeline and a whole lot of expiring patents. Longterm I see growth, shortterm, lots of pain medication and suffering.

Investing in precious metals often requires a belief that inflationary pressures will devalue the currency, making gold, silver, and the like more valuable. While we are perhaps entering into a deflationary period right now, CAPS member ardyes703 sees the bill coming due on this year's deluge of government intervention, which will boost Silver Wheaton. And with the next president promising a public works program the likes of which hasn’t been seen since the 1950s, there is a groundswell of pressure building beneath precious metals prices; ardyes703 writes:

It's not surprise that commodities have been pummeled this year along with their paper counterparts; their respective stocks ([SPDR Gold Shares], [Apex Silver Mines], etc...) Silver Wheaton though is special. Not only are they still performing admirably considering spot silver is down about 50% from its $17/oz highs, but because their fixed cost contracts give them a huge edge over the competition. Face it, spot silver will not stay in the single-digits for long, especially in 2009-2010 when the hangover of "bail-out" mania devalues the US$even further. This is why [Silver Wheaton] is my 12-month play of the year.

Ahoy there!
Whether you've been in the markets for years or are brand-new to the investing world, it pays to start your own research on these stocks on Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made, all from a stock's CAPS page. Then share your views with the CAPS community on whether these old salts have the wind in their sails.

Follow along with the Global Gains team as they travel to key business centers in China to uncover the very best investing opportunities! Sign up here to receive their FREE dispatches from the road.

Garmin is a Motley Fool Global Gains pick. Pfizer, Eli Lilly, and GlaxoSmithKline are Motley Fool Income Investor picks. Pfizer is a Motley Fool Inside Value recommendation. Garmin is a Motley Fool Stock Advisor selection. The Fool owns shares of Pfizer. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 789895, ~/articles/ArticleHandler.aspx, 7/4/2009 11:42:25 PM

Keep Reading:

“5 Stocks to Steer Through Rough Waters”

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Get involved! »

Most Recent

Jul 2 at 4:22 PM

Market Summary

DJIA 8,280.74 -223.32 -2.63%
S&P 500 896.42 -26.91 -2.91%
NASD 1,796.52 +0.00 +0.00%
Sponsored by:

Related Tickers

Pfizer, Inc.

CAPS Rating 4/5 Stars

$14.48

-0.42 (-2.82%)

Outperform4927

Underperform574

Rate This Stock